论文部分内容阅读
目的观察肺表面活性物质预防新生儿呼吸窘迫综合征(NRDS)的临床疗效。方法将68例存在呼吸困难症状的早产儿随机分为观察组35例和对照组33例。对照组给予常规治疗,观察组在常规治疗基础上给予肺表面活性物质治疗,对比2组NRDS发生率、血气结果、呼吸急促、发绀情况和并发症发生率。结果观察组NRDS发生率、出现呼吸急促和发绀症状的几率以及治疗后并发症发生率均显著低于对照组,差异均有统计学意义(P<0.05);血气分析显示观察组动脉血氧分压(Pa O2)及p H显著高于对照组,动脉血二氧化碳分压(Pa CO2)显著低于对照组,差异均有统计学意义(P<0.05)。结论肺表面活性物质对NRDS有显著预防效果,可促使并发症发生率显著降低,值得在临床中推广。
Objective To observe the clinical efficacy of pulmonary surfactant in the prevention of neonatal respiratory distress syndrome (NRDS). Methods Sixty-eight preterm infants with dyspnea were randomly divided into observation group (35 cases) and control group (33 cases). The control group was given routine treatment. The observation group was given pulmonary surfactant treatment on the basis of routine treatment. The incidence of NRDS, blood gas, shortness of breath, cyanosis and complication rate were compared between the two groups. Results The incidence of NRDS, the incidence of shortness of breath and cyanosis and the incidence of postoperative complications in the observation group were significantly lower than those in the control group (P <0.05). The blood gas analysis showed that the arterial oxygen level PaO2 and pH were significantly higher than those in the control group. PaCO2 in arterial blood was significantly lower than that in control group (P <0.05). Conclusion Pulmonary surfactant has a significant preventive effect on NRDS, which can significantly reduce the incidence of complications and is worth popularizing in clinic.